Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China |
| |
| Institution: | 1. National Institute for Communicable Disease Control and Prevention, State Key Laboratory for Infectious Disease Prevention and Control, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of China;2. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, People’s Republic of China;3. Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of China;4. School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China;5. Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, People’s Republic of China;1. Departments of Experimental Medicine and Medical Statistics, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Jiangsu, China;2. Department of Infectious Diseases, Changzhou Third People''s Hospital, Jiangsu, China;3. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Jiangsu, China;4. Department of Infectious Diseases, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Jiangsu, China;1. Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands;2. Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands;3. Department of Immunology and Infectious Diseases, University Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht, The Netherlands;4. Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center, Amsterdam, The Netherlands;1. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China;2. National Institutes for Food and Drug Control, Beijing, China;3. Minhai Biotechnology Co., Ltd., Beijing, China;1. Laboratorio de (Epi)Genética Molecular, Instituto de Investigación Sanitaria BioAraba, Hospital Universitario Araba-Txagorritxu, BioAraba, Vitoria-Gasteiz, Álava, España;2. Endocrinología Infantil, Hospital General Universitario, Elda, Alicante, España;3. Servicio de Pediatría, Hospital San Agustín, Avilés, Asturias, España;4. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER U724), Madrid, España |
| |
| Abstract: | ObjectiveTo study the prevalence of the fHbp genes in Neisseria meningitidis (N. meningitidis) isolates for further evaluation and development of serogroup B meningococcal vaccines in China.MethodsA panel of 1012 N. meningitidis strains was selected from the national culture collection from 1956 to 2016, according to the years of isolation, locations, and strain sources. These were tested by FHbp variant typing. Multi-locus sequence typing (MLST) was performed on 822 of these samples, including 242 strains from clinical strains and 580 carrier-derived strains. Analysis based on sequence types, serogroups, and FHbp variations were used to summarize the prevalence and characteristics of N. meningitidis.ResultsThere were 8 serogroups of N. meningitidis as well as a collection of nongroupable strains in this study. 1008 of 1012 N. meningitidis strains tested were positive for the fHbp gene. Serogroup A N. meningitidis (MenA) strains belonging to ST-1 and ST-5 clonal complexes harbored genes only encoding variant 1 (v1) FHbp. All MenW strains encoded v2 FHbp. 61.9% of clinical MenB strains were positive for v2 FHbp vs. 32.1% that were positive for v1. Among fHbp-positive carrier-derived MenB strains, v2 FHbp accounted for 90.8%. 79.7% of clinical MenC strains were positive for v1 FHbp and 20.3% were positive for v2 FHbp. Among carrier-derived MenC strains, v2 FHbp predominated. The number of major serogroups of N. meningitidis analyzed by MLST was 822, and the encoded FHbp showed CC- or ST-specific characteristics.ConclusionfHbp genes were detected in almost all N. meningitidis strains in this study. Therefore, it is possible that a vaccine against MenB or meningococci irrespective of serogroups, which includes FHbp, could be developed. Meningococcal vaccine development for China is a complex issue and these findings warrant further attention with respect to vaccine development. |
| |
| Keywords: | Factor H Binding Protein Vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
